Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
9014 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4365
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Acalabrutinib NCT07582159 · Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymph… | Sclérose en plaques | À vérifier | Phase 2 | NOT_YET_RECRUITING | The purpose of this study is to investigate the efficacy and safety of fix… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:29 | Détail |
| anti-CD19 CAR T cell therapy NCT06828042 · Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Auto… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1/2 | RECRUITING | Autoimmune diseases refer to a common category of diseases caused by the i… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:29 | Détail |
| CD19 CARvac T cells NCT04156243 · CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies | Sclérose en plaques | Immunomodulation | Phase 1 | UNKNOWN | This is a phase I, interventional, single arm, open label, treatment study… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:29 | Détail |
| CD19-BAFF Targeted CAR T-cells NCT06279923 · CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therap… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:29 | Détail |
| Human CD19 targeted T Cells Injection NCT03720457 · Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | UNKNOWN | To evaluate the safety and tolerance of human CD19 targeted T Cells inject… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:29 | Détail |
| Alemtuzumab NCT00818961 · Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer | Sclérose en plaques | Remyélinisation · Immunomodulation · Thérapie cellulaire | Phase 2 | TERMINATED | The MRI study is designed to identify possible mechanisms by which alemtuz… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| Anti-CD19 iCAR NK Cells NCT03824951 · Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma | Sclérose en plaques | Immunomodulation | Phase 1 | UNKNOWN | This is a single-centre, single-arm and open-label study to investigate th… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| Asparaginase NCT02538926 · Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hy… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | This phase II trial studies how well etoposide, prednisone, vincristine su… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells NCT04486872 · An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differenti… | Sclérose en plaques | Immunomodulation | Phase 1 | UNKNOWN | This is a single-arm, open-label, dose escalation, phase I study, aiming t… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| Filgrastim NCT00003595 · Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating… | Sclérose en plaques | À vérifier | Phase 3 | COMPLETED | This phase Ib/II trial studies the best dose and side effects of venetocla… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| Radiotracer [11C]-CS1P1 NCT06591429 · Smoldering Inflammation in MS | Sclérose en plaques | Immunomodulation · Thérapie génique | À vérifier | RECRUITING | The goal of this observational study is to learn about inflammation in tho… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| SIBP-02 NCT04361279 · A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untr… | Sclérose en plaques | Immunomodulation | Phase 3 | COMPLETED | This is a randomised, double-blind, positive drug parallel controlled equi… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| TQB2825 Injection (Subcutaneous Injection) NCT07110194 · Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hemato… | Sclérose en plaques | Immunomodulation | Phase 1 | NOT_YET_RECRUITING | The aim of this study is to evaluate the pharmacokinetic characteristics,… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| Venetoclax NCT03379051 · Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab a… | Sclérose en plaques | Thérapie cellulaire · Thérapie génique | Phase 1/2 | TERMINATED | This study evaluates the effectiveness and safety of a new conditioning re… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:28 | Détail |
| C-CAR168 NCT07854483 · A Phase 1b Study of C-CAR168 in Participants With Systemic Sclerosis (SSc) | Sclérose en plaques | Immunomodulation · Thérapie génique | Phase 1 | NOT_YET_RECRUITING | This Phase 2, multicenter, open-label study will evaluate the safety and e… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:27 | Détail |
| Theophylline NCT01066728 · CO2 Inhalation as a New Treatment Modality for Apnea of Prematurity | Sclérose en plaques | À vérifier | Phase 2/3 | COMPLETED | To evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokin… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:23 | Détail |
| ambrisentan and theophylline NCT01902758 · Drug Combination on Exercise Performance at High Altitude | Sclérose en plaques | Traitement symptomatique | Phase 2/3 | COMPLETED | This study is being conducted to determine the effectiveness of using two… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:22 | Détail |
| Symbicort, used twice daily (b.i.d) and as needed (prn) NCT00252863 · DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and C… | Sclérose en plaques | À vérifier | Phase 3 | COMPLETED | The purpose of this study is to determine whether Symbicort dosed accordin… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:22 | Détail |
| Theophylline NCT03115294 · CardiomeDIC — Digital Image Correlation in Right Ventricular Evaluation | Sclérose en plaques | À vérifier | Non applicable | COMPLETED | To evaluate the effect of multiple doses of BIIL 284 BS on the pharmacokin… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:22 | Détail |
| Acamprosate calcium NCT07204977 · Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Scler… | Sclérose latérale amyotrophique | Traitement symptomatique | Phase 1 | RECRUITING | Description non affichée : incohérence de maladie détectée. Consultez l’es… À vérifier | ClinicalTrials.gov 2026-10-04 04:37:09 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4628
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Responsive stimulation of the thalamus for idiopathic generalized epi… RNS® System · PMID 42233958 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source This study was undertaken to evaluate the safety and effectiveness of responsive thalamic stimulation as adjunctive the… | Epilepsia 2026-07-08 12:06:44 | Source |
| Thalamocortical seizure onset patterns in drug-resistant focal epilep… RNS® System · PMID 42396599 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Drug-resistant epilepsy affects tens of millions of people worldwide and is associated with considerable morbidity and… | Brain communications 2026-07-08 12:06:44 | Source |
| A review of the efficacy and safety of eslicarbazepine acetate in the… BIA 2-093 · PMID 26136845 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Eslicarbazepine acetate is a is a once-daily antiepileptic drug (AED) that was approved in 2009 by the European Medicin… | Therapeutic advances in neurological disorders 2026-07-08 12:06:42 | Source |
| K7 and K Potassium Channels in Thalamocortical Function and Their The… Effects of Antiepileptic Drugs on Brain Excitability · PMID 42261627 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source Potassium (K) channels are one of the key regulators of neuronal excitability and network stability. Among all the pota… | Archiv der Pharmazie 2026-07-08 12:06:42 | Source |
| Lateral Habenula 5-HT₂A Receptors Mediate Social Deficits in a Valpro… Effects of Antiepileptic Drugs on Brain Excitability · PMID 42277370 | Épilepsie | Traitement symptomatique | Publication | PubMed | Voir la publication source Autism Spectrum Disorder (ASD) is characterized by social deficits, yet underlying neural mechanisms remain poorly unde… | Molecular neurobiology 2026-07-08 12:06:42 | Source |
| Progress report on new antiepileptic drugs: a summary of the Ninth Ei… BIA 2-093 · PMID 19008076 | Épilepsie | À vérifier | Publication | PubMed | Voir la publication source The Ninth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT IX, took place in Sitges, Barcelona from the 15th to… | Epilepsy research 2026-07-08 12:06:42 | Source |
| Diagnostic performance of [18F]FDG PET/CT in large vessel vasculitis… 18F-FDG · PMID 42411928 | Cancer · Épilepsie · Épilepsie | Immunomodulation | Publication | PubMed | Voir la publication source Large vessel vasculitis (LVV), encompassing giant cell arteritis (GCA), Takayasu arteritis (TAK) and polymyalgia rheuma… | The quarterly journal of nuclear medicine and molecula… 2026-07-08 12:06:41 | Source |
| Divergent Radiomolecular Phenotype of Spindle Cell Lipoma: Inten… 18F-FDG · PMID 42411770 | Cancer | À vérifier | Publication | PubMed | Voir la publication source A 68-year-old man with gastric cancer underwent 18F-fluorodeoxyglucose (FDG) PET/CT, which revealed an incidental subcu… | Clinical nuclear medicine 2026-07-08 12:06:41 | Source |
| Intermittent theta burst stimulation enhances the efficacy of brain-c… Intermittent theta burst stimulation · PMID 42404120 | Maladie d’Alzheimer · Myopathies · Maladie de Parkinson · Maladie d’A… | À vérifier | Publication | PubMed | Voir la publication source "BCI illiteracy," characterized by insufficient -rhythm Event-Related Desynchronization (ERD) in approximately 40% of s… | Frontiers in neurology 2026-07-08 12:06:40 | Source |
| Subchronic comparative assessment of graded ferrous sulfate doses on… 0.9% NaCl · PMID 42376110 | Maladie d’Alzheimer | Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source Iron is a necessary trace element in the human body. However, excessive concentration can promote the overproduction of… | Open veterinary journal 2026-07-08 12:06:39 | Source |
| Sustainable soil improvement strategies for coral islands: Synergisti… 0.9% NaCl · PMID 42379437 | Maladie d’Alzheimer | À vérifier | Publication | PubMed | Voir la publication source The sustainable development of coral islands is constrained by bottleneck issues such as poor water retention and nutri… | International journal of biological macromolecules 2026-07-08 12:06:39 | Source |
| Minaxolone: an evaluation with and without premedication. Allopregnanolone injection (intravenous solution) · PMID 7270828 | Maladie d’Alzheimer | Traitement symptomatique | Publication | PubMed | Voir la publication source Minaxolone, a water-soluble steroid intravenous anaesthetic, has been used in clinical trials for induction and mainten… | Anaesthesia 2026-07-08 12:06:38 | Source |
| Continuous theta burst stimulation to the frontal pole durably decrea… Continuous theta burst stimulation · PMID 42379239 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The frontal pole is a transdiagnostic target for affective disorders, perhaps through its connectivity with affective r… | International review of psychiatry (Abingdon, England) 2026-07-08 12:06:37 | Source |
| Role of the Upper Motor Neuron in the Generation of Fasciculations in… Continuous theta burst stimulation · PMID 42407013 | Sclérose latérale amyotrophique | À vérifier | Publication | PubMed | Voir la publication source The origin of fasciculation potentials (FPs) in the early stages of amyotrophic lateral sclerosis (ALS) remains a subje… | Neurology 2026-07-08 12:06:37 | Source |
| Extrapontine Myelinolysis and Reversible Parkinsonism After Hyponatre… Levodopa/carbidopa solution for SC administration · PMID 30055367 | Maladie de Parkinson | Traitement symptomatique | Publication | PubMed | Voir la publication source Osmotic demyelination syndrome commonly follows rapid correction of hyponatremia. Although pons is a common location, e… | World neurosurgery 2026-07-08 12:06:36 | Source |
| Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson'… Levodopa/carbidopa solution for SC administration · PMID 33772855 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The aim was to demonstrate that continuous s.c. infusion of a soluble levodopa (LD)/carbidopa (CD) phosphate prodrug co… | Annals of neurology 2026-07-08 12:06:36 | Source |
| Between Surgery and Science: Patient Journeys in Deep Brain Stimulati… Determining Patterns In Trial Experiences of Parkinson's Disease Patients · PMID 41910515 | Maladie de Parkinson | Thérapie génique | Publication | PubMed | Voir la publication source For the past 25 years, local field potential (LFP) recordings from externalized deep brain stimulation (DBS) leads have… | Neuromodulation : journal of the International Neuromo… 2026-07-08 12:06:35 | Source |
| Technology Acceptance of 2 mHealth Apps During an Observational Techn… Determining Patterns In Trial Experiences of Parkinson's Disease Patients · PMID 42061832 | Maladie de Parkinson | Immunomodulation · Traitement symptomatique | Publication | PubMed | Voir la publication source Mobile health (mHealth) apps are useful tools for research and disease management. However, implementation of mHealth a… | JMIR human factors 2026-07-08 12:06:35 | Source |
| The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in… ACP-103 · PMID 37627285 | Maladie de Parkinson | Traitement symptomatique | Publication | PubMed | Voir la publication source Almost 25% of schizophrenia patients suffer from obsessive-compulsive symptoms (OCS) considered a transdiagnostic clini… | Biomolecules 2026-07-08 12:06:34 | Source |
| Unlocking the potential of lumateperone and novel anti-psychotics for… ACP-103 · PMID 40161932 | Maladie de Parkinson | Traitement symptomatique | Publication | PubMed | Voir la publication source Schizophrenia is a devastating chronic mental health illness which includes a complex set of symptoms like hallucinatio… | BioImpacts : BI 2026-07-08 12:06:34 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||